Khagendra Dahal1, Sharan P Sharma2, Erik Fung3, Juyong Lee4, Jason H Moore5, John N Unterborn6, Scott M Williams7. 1. Department of Medicine, LRGHealthcare, Laconia, NH. Electronic address: kdahal@lrgh.org. 2. Department of Medicine, Englewood Hospital and Medical Center, Englewood, NJ. 3. Section of Cardiology, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Geisel School of Medicine, Dartmouth College, Hanover, NH. 4. Calhoun Cardiology, University of Connecticut Health Center, Farmington, CT. 5. Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Geisel School of Medicine, Dartmouth College, Hanover, NH; Department of Genetics, Dartmouth College, Hanover, NH; Institute of Quantitative Biomedical Science, Dartmouth College, Hanover, NH. 6. Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA. 7. Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Department of Genetics, Dartmouth College, Hanover, NH; Institute of Quantitative Biomedical Science, Dartmouth College, Hanover, NH.
Abstract
BACKGROUND: Warfarin is a widely prescribed anticoagulant, and its effect depends on various patient factors including genotypes. Randomized controlled trials (RCTs) comparing genotype-guided dosing (GD) of warfarin with standard dosing have shown mixed efficacy and safety outcomes. We performed a meta-analysis of all published RCTs comparing GD vs standard dosing in adult patients with various indications of warfarin use. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and relevant references for English language RCTs (inception through March 2014). We performed the meta-analysis using a random effects model. RESULTS: Ten RCTs with a total of 2,505 patients were included in the meta-analysis. GD compared with standard dosing resulted in a similar % time in therapeutic range (TTR) at ≤ 1 month follow-up (39.7% vs 40.2%; mean difference [MD], -0.52 [95% CI, -3.15 to 2.10]; P = .70) and higher % TTR (59.4% vs 53%; MD, 6.35 [95% CI, 1.76-10.95]; P = .007) at > 1 month follow-up, a trend toward lower risk of major bleeding (risk ratio, 0.46 [95% CI, 0.19-0.1.11]; P = .08) at ≤ 1 month follow-up and lower risks of major bleeding (0.34 [95% CI, 0.16-0.74], P = .006) at > 1-month follow-up, and shorter time to maintenance dose (TMD) (24.6 days vs 34.1 days; MD, -9.54 days [95% CI, -18.10 to -0.98]; P = .03) at follow-up but had no effects on international normalized ratio [INR] > 4.0, nonmajor bleeding, thrombotic outcomes, or overall mortality. CONCLUSIONS: In the first month of genotype-guided warfarin therapy, compared with standard dosing, there were no improvements in % TTR, INR > 4.0, major or minor bleeding, thromboembolism, or all-cause mortality. There was a shorter TMD, and, after 1 month, improved % TTR and major bleeding incidence, making this a cost-effective strategy in patients requiring longer anticoagulation therapy.
BACKGROUND:Warfarin is a widely prescribed anticoagulant, and its effect depends on various patient factors including genotypes. Randomized controlled trials (RCTs) comparing genotype-guided dosing (GD) of warfarin with standard dosing have shown mixed efficacy and safety outcomes. We performed a meta-analysis of all published RCTs comparing GD vs standard dosing in adult patients with various indications of warfarin use. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and relevant references for English language RCTs (inception through March 2014). We performed the meta-analysis using a random effects model. RESULTS: Ten RCTs with a total of 2,505 patients were included in the meta-analysis. GD compared with standard dosing resulted in a similar % time in therapeutic range (TTR) at ≤ 1 month follow-up (39.7% vs 40.2%; mean difference [MD], -0.52 [95% CI, -3.15 to 2.10]; P = .70) and higher % TTR (59.4% vs 53%; MD, 6.35 [95% CI, 1.76-10.95]; P = .007) at > 1 month follow-up, a trend toward lower risk of major bleeding (risk ratio, 0.46 [95% CI, 0.19-0.1.11]; P = .08) at ≤ 1 month follow-up and lower risks of major bleeding (0.34 [95% CI, 0.16-0.74], P = .006) at > 1-month follow-up, and shorter time to maintenance dose (TMD) (24.6 days vs 34.1 days; MD, -9.54 days [95% CI, -18.10 to -0.98]; P = .03) at follow-up but had no effects on international normalized ratio [INR] > 4.0, nonmajor bleeding, thrombotic outcomes, or overall mortality. CONCLUSIONS: In the first month of genotype-guided warfarin therapy, compared with standard dosing, there were no improvements in % TTR, INR > 4.0, major or minor bleeding, thromboembolism, or all-cause mortality. There was a shorter TMD, and, after 1 month, improved % TTR and major bleeding incidence, making this a cost-effective strategy in patients requiring longer anticoagulation therapy.
Authors: John W Eikelboom; Stuart J Connolly; Martina Brueckmann; Christopher B Granger; Arie P Kappetein; Michael J Mack; Jon Blatchford; Kevin Devenny; Jeffrey Friedman; Kelly Guiver; Ruth Harper; Yasser Khder; Maximilian T Lobmeyer; Hugo Maas; Jens-Uwe Voigt; Maarten L Simoons; Frans Van de Werf Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245
Authors: Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Benjamin D Horne; Petra A Lenzini; Mia Wadelius; Andrea L Jorgensen; Stephen E Kimmel; Paul M Ridker; Niclas Eriksson; Jeffrey L Anderson; Munir Pirmohamed; Nita A Limdi; Robert C Pendleton; Gwendolyn A McMillin; James K Burmester; Daniel Kurnik; C Michael Stein; Michael D Caldwell; Charles S Eby; Anders Rane; Jonatan D Lindh; Jae-Gook Shin; Ho-Sook Kim; Pantep Angchaisuksiri; Robert J Glynn; Kathryn E Kronquist; John F Carlquist; Gloria R Grice; Robert L Barrack; Juan Li; Brian F Gage Journal: Thromb Haemost Date: 2011-12-21 Impact factor: 5.249
Authors: Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore Journal: Semin Thromb Hemost Date: 2012-10-06 Impact factor: 4.180
Authors: Mark P Borgman; Robert C Pendleton; Gwendolyn A McMillin; Kristen K Reynolds; Sara Vazquez; Andrew Freeman; Andrew Wilson; Roland Valdes; Mark W Linder Journal: Thromb Haemost Date: 2012-07-26 Impact factor: 5.249
Authors: James K Burmester; Richard L Berg; Steven H Yale; Carla M Rottscheit; Ingrid E Glurich; John R Schmelzer; Michael D Caldwell Journal: Genet Med Date: 2011-06 Impact factor: 8.822
Authors: E J Do; P Lenzini; C S Eby; A R Bass; G A McMillin; S M Stevens; S C Woller; R C Pendleton; J L Anderson; P Proctor; R M Nunley; V Davila-Roman; B F Gage Journal: Pharmacogenomics J Date: 2011-05-24 Impact factor: 3.550
Authors: Letícia C Tavares; Nubia E Duarte; Leiliane R Marcatto; Renata A G Soares; Jose E Krieger; Alexandre C Pereira; Paulo Caleb Junior Lima Santos Journal: Eur J Clin Pharmacol Date: 2018-07-26 Impact factor: 2.953
Authors: Gary Tse; Mengqi Gong; Guangping Li; Sunny Hei Wong; William K K Wu; Wing Tak Wong; Leonardo Roever; Alex Pui Wai Lee; Gregory Y H Lip; Martin C S Wong; Tong Liu Journal: Br J Clin Pharmacol Date: 2018-06-21 Impact factor: 4.335
Authors: Marcus Fernando S Praxedes; Maria Auxiliadora P Martins; Aline O M Mourão; Karina B Gomes; Edna A Reis; Renan P Souza; Emílio Itamar F Campos; Daniel D Ribeiro; Manoel Otávio C Rocha Journal: Eur J Clin Pharmacol Date: 2019-11-12 Impact factor: 2.953
Authors: Nicholas L Syn; Andrea Li-Ann Wong; Soo-Chin Lee; Hock-Luen Teoh; James Wei Luen Yip; Raymond Cs Seet; Wee Tiong Yeo; William Kristanto; Ping-Chong Bee; L M Poon; Patrick Marban; Tuck Seng Wu; Michael D Winther; Liam R Brunham; Richie Soong; Bee-Choo Tai; Boon-Cher Goh Journal: BMC Med Date: 2018-07-10 Impact factor: 8.775
Authors: Cristina Lucía Dávila-Fajardo; Xando Díaz-Villamarín; Alba Antúnez-Rodríguez; Ana Estefanía Fernández-Gómez; Paloma García-Navas; Luis Javier Martínez-González; José Augusto Dávila-Fajardo; José Cabeza Barrera Journal: Genes (Basel) Date: 2019-04-01 Impact factor: 4.096
Authors: Justin B Kaye; Lauren E Schultz; Heidi E Steiner; Rick A Kittles; Larisa H Cavallari; Jason H Karnes Journal: Pharmacotherapy Date: 2017-09-06 Impact factor: 4.705